At least one in 4,500 individuals are affected with mitochondrial diseases caused by defects in genes affecting the function of mitochondria, a crucial energy-producing structures found in every cell. However, the standard care for treating these diseases is not uniform. Physicians now have a practical new tool--a set of guidelines for managing and caring for patients with mitochondrial diseases.
"Standards of care are not uniform across centers or clinicians. To take just one example, clinicians need to know how often to order laboratory tests to monitor the health of patients with mitochondrial disease," said study co-leader Amy Goldstein, MD, newly appointed clinical director of the Mitochondrial Medicine Frontier Program at Children's Hospital of Philadelphia (CHOP), and current president of the Mitochondrial Medicine Society (MMS), which issued the consensus statement. "Our guidelines reflect expert consensus based on our current knowledge of mitochondrial medicine."
High Costs of Mitochondrial Diseases Spell Urgent Need for Better Therapies
Mutated genes may cause a group of disorders called as Mitochondrial diseases. The high cost of these disorders may point the urgent need for better therapies.
The MMS patient care standards for primary mitochondrial disease appeared online July 27, 2017 in Genetics in Medicine. The study leader and corresponding author is Sumit Parikh, MD, of the Cleveland Clinic Children's Hospital.
New Online Database Provides Answers On Mitochondrial Diseases
A new tool has been created called the POLG Pathogenicity Prediction Server. POLG helps clinicians and scientists to diagnose POLG disorders more accurately.
For the current study, the MMS appointed an international panel of 35 mitochondrial medicine specialists to review current knowledge and develop recommendations.
Reflecting the systemic impact of energy deficiencies caused by impaired mitochondrial function, the group's recommendations address a broad range of medical specialties, including cardiology, neurology, critical care medicine, nephrology, endocrinology, audiology and ophthalmology.
In addition, the guidelines address special issues encountered by patients during pregnancy and high-altitude travel, and also compile a list of medications, such as statins and acetaminophen, that must be used with caution or avoided in patients with mitochondrial disease.
While the current guidelines are the first set of published recommendations for patient management and clinical care decisions, the authors recognize that as mitochondrial medicine continues to evolve, the guidelines will need to be updated.
These guidelines represent an important step in the effort to standardize health care and optimize health outcomes for mitochondrial disease patients. They also establish a baseline from which meaningful clinical trials can be launched to evaluate new treatment interventions.
Source: Eurekalert
Novel Discovery Could Lead to Treatments for Mitochondrial Diseases
Embryos with 'heteroplasmy', or the presence of both maternal and paternal mitochondrial DNA, have been successfully created by researchers from University of Missouri.
 Mitochondrial Diseases Have a Remedy by 'Three Parent' Invitro FertilisationThe IVF procedure involves the use of biological material from three "parents" to prevent the illnesses. | Advertisement
|
Latest General Health News
